Effects of Sitagliptin combined with Metformin in treatment of elderly patients with type 2 diabetes mellitus
Objective:To observe effects of Sitagliptin combined with Metformin in treatment of elderly patients with type 2 diabetes mellitus(T2DM).Methods:A prospective study was conducted on 96 elderly patients with T2DM admitted to the hospital from January 2022 to January 2024.According to the random number table method,they were divided into study group and control group,48 cases in each group.The control group was treated with Metformin,while the study group was treated with Sitagliptin on the basis of that of the control group.The levels of glucose metabolism indexes[fasting blood glucose(FPG),2 h postprandial blood glucose(2hPG),glucagon-like peptide-1(GLP-1)],lipid metabolism indexes[total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),triacylglycerol(TG)],islet function indexes[fasting insulin(FINS),insulin resistance index(HOMA-IR)]and inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6)]before and after the treatment,and the incidence of adverse reactions were compared.Results:After the treatment,the levels of FPG and 2hPG in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,the levels of GLP-1 in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of TG,TC and LDL-C in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;the levels of HDL-C in the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the FINS levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the HOMA-IR levels of the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP and IL-6 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sitagliptin combined with Metformin in the treatment of the elderly patients with T2DM can improve the levels of lipid metabolism indexes and islet function indexes,and reduce the levels of glucose metabolism indexes and inflammatory factors.Moreover,it is superior to simple Metformin treatment.
NETL
NSTL
万方数据
